8-K: Jaguar Health Reports Q2 2026 Results, Revenue Down 59%

Jaguar Health announced its second quarter 2026 financial results, reporting a 59% decrease in total revenue to $1.2 million and a widened net loss of $12.7 million.

Summary

• Jaguar Health reported its second quarter 2026 financial results on August 19, 2026.
• Total revenue for the quarter was $1.2 million, a 59% decrease from $2.9 million in Q2 2025.
• Prescription product revenue, primarily from Mytesi and Canalevia-CA1, was $1.2 million, down 60% year-over-year.
• License and grant revenue remained flat at $43,000.
• Loss from operations decreased by 5% to $7.6 million, offset by a reduction in operating expenses.
• Net loss attributable to common stockholders increased by 22% to $12.7 million, or $15.68 per share.
• Non-GAAP recurring EBITDA was a net loss of $8.4 million, compared to $7.9 million in Q2 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue decline and increased net loss, despite progress in R&D and strategic licensing.

Positives

• The company has a U.S. commercial licensing agreement with Woodward Specialty, LLC (an affiliate of Future Pak, LLC) for Mytesi and Canalevia-CA1, which has reduced commercial costs.
• The number of Mytesi bottles sold in Q2 2026 increased significantly compared to Q2 2025.
• Research and Development expenses increased slightly to $3.3 million, primarily due to progress in developing a powder formulation of crofelemer for rare diseases.
• Sales and Marketing expenses decreased substantially by $2.5 million due to the licensing agreement.
• General and Administrative expenses decreased by $0.3 million due to reduced legal, compliance, and public company expenses.
• Loss from operations decreased by $0.4 million due to reduced operating expenses offsetting lower revenue.

Negatives

• Total revenue decreased by 59% to $1.2 million in Q2 2026 compared to $2.9 million in Q2 2025.
• Prescription product net revenue decreased by 60% to $1.2 million in Q2 2026 compared to $2.9 million in Q2 2025.
• Net loss attributable to common stockholders increased by 22% to $12.7 million in Q2 2026 from $10.4 million in Q2 2025.
• Non-GAAP recurring EBITDA showed a net loss of $8.4 million in Q2 2026, an increase from $7.9 million in Q2 2025.
• Cost of product revenue increased by $0.5 million due to sales of inventory to Future Pak.
• Interest expense increased by $176,000.
• Fair value adjustments for financial instruments resulted in an increased loss of $0.9 million.
• Loss on extinguishment of debt increased by $1.7 million.

Risks

• The company's financial performance is heavily reliant on the success of its licensing agreements and the development of crofelemer for rare intestinal failure diseases.
• The significant decrease in prescription product revenue raises concerns about market penetration and sales performance of existing products.
• The increased net loss and negative EBITDA indicate ongoing financial challenges.
• The company's ability to achieve regulatory approval and commercialize its powder formulation of crofelemer is subject to uncertainties.
• Forward-looking statements are subject to risks, uncertainties, and assumptions beyond the company's control.

Future Outlook

The company expects the clinical package for the New Drug Application (NDA) for crofelemer for microvillus inclusion disease (MVID) to be ready by the end of 2026, with submission anticipated in the second quarter of 2027. Jaguar also expects its powder formulation of crofelemer for rare disease intestinal failure clinical trials to receive regulatory approval and be approved for commercialization.

Management Comments

• The company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases.
• Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patients with the ultrarare microvillus inclusion disease (MVID).
• The decision to enter a commercial license agreement with Future Pak aligns with Jaguar's strategic focus on advancing the development of its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans.

Industry Context

StockSavvy.ai notes that Jaguar Health's focus on rare intestinal failure diseases with crofelemer positions it in a niche but potentially high-value segment of the pharmaceutical market. The shift towards a licensing model for established products like Mytesi and Canalevia-CA1 reflects a common strategy for smaller biopharma companies to conserve resources for pipeline development, though it significantly impacts reported revenue.

Related Party Transactions

• Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of Future Pak, LLC, for Mytesi and Canalevia-CA1. Napo, a Jaguar family company, remains the manufacturer and supplies product to Future Pak at cost-plus terms.

Stakeholder Impact

• Shareholders: The significant revenue decline and increased net loss may negatively impact shareholder value and confidence.
• Employees: The strategic shift and reduced commercial operations could lead to workforce adjustments.
• Suppliers: The licensing agreement with Future Pak alters the supply chain dynamics for Mytesi and Canalevia-CA1.
• Creditors: The increased net loss and ongoing operational expenses may affect the company's ability to service debt.

Next Steps

• Prepare the clinical package for the NDA for crofelemer for MVID by the end of 2026.
• Submit the NDA for crofelemer for MVID in Q2 2027.
• Continue development of the powder-for-oral-solution formulation of crofelemer for rare disease indications.
• Host investor webcasts for financial and company updates.

Key Dates

Recommendation

The filing indicates a significant decline in revenue and an increase in net loss, which are concerning trends. While there is progress in R&D for rare diseases, the core business performance is deteriorating. The strategic shift to licensing, while reducing costs, has drastically cut reported revenue, and the path to profitability remains uncertain given the current financial trajectory.

Keywords

crofelemer, intestinal failure, MVID, Mytesi, Canalevia-CA1, rare diseases, licensing agreement, financial results